ONeil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, et al

What is already known on this topic Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a promising drug class that has shown benefits for adults with type 2 diabetes Regulatory authorities have approved several GLP-1RA drugs, and novel drugs are continually emerging, resulting in an urgent need for updated evidence synthesis of the comparative effectiveness of various GLP-1RAs What this study adds Compared with the placebo, all 15 GLP-1RAs had significant effects on glycaemic control, and tirzepatide was the most effective in reducing haemoglobin A 1c and fasting plasma glucose concentrations CagriSema induced the highest weight reduction in adults with type 2 diabetes, followed by tirzepatide and retatrutide Several GLP-1RAs resulted in a significantly higher odds ratio of discontinuation due to adverse events than placebo, raising safety concerns about gastrointestinal adverse events, especially at high doses Ethics statements Ethical approval Not required

Semaglutide Alternatives Between a high price tag, tight supply (Mounjaro and Zepbound are both showing limited availability through the second quarter) and general uneasiness about the unknown and possible long-term effects of weight loss medications, some products have begun to hit the market offering an affordable alternative
[DOI] [PMC free article] [PubMed] [Google Scholar] 37.Khosravi A., Ghodsi S., Memarjafari M., Nematollahi A., Sheikh-Sharbafan R., Sadre-Bafghi S.A., Moosavi S.V., Abdollahzadeh M., Jalali A., Farahani M.M
Indicated for external application to the skin and compatible with professional cosmetic protocols for virtual mesotherapy, superficial cosmetic microneedling and non-invasive transdermal delivery systems using professional equipment